B

Bioventix

Organization

Heard in 2 episodes across 1 show since Mar 2026

A UK biotechnology company that develops and commercializes high-affinity antibodies used in diagnostic tests, particularly in clinical laboratories.

Episodes

2
across 1 show

First heard

Mar 2026

Expert statements

4
1 positive · 3 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20261
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261
Nov 20260

Email alert

Email me when Bioventix comes up on a podcast

One email a week at most, with the new episodes that mention Bioventix. Free, no account needed, unsubscribe in one click.

What experts have said about Bioventix

4 statements · 1 positive · 3 negative

  1. Bioventix’s share price has fallen sharply and persistently.

    “I think most— Bioventix is another one that used to be such a quality growth stock, but the share price is just a 45-degree line downwards.”

    Listen at 32:53

    Open the episode · Paul's Podcast - Fri 13 Mar 2026
  2. Bioventix’s 10.5% dividend yield signals doubts about dividend sustainability.

    “£75 million market cap, 10.5% dividend yield, which is saying to you the market doesn't think the dividends are sustainable.”

    Listen at 33:06

    Open the episode · Paul's Podcast - Fri 13 Mar 2026
  3. Bioventix’s 10.5% yield signals doubts about dividend sustainability.

    “10.5% dividend yield, which is saying to you the market doesn't think the dividends are sustainable.”

    Listen at 33:09

    Open the episode · Paul's Podcast - Fri 13 Mar 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Bioventix, newest first